BioSpace News Archive

AVEO Oncology reported financial results for the first quarter ended March 31, 2019 and provided a business update.

On Track to Initiate Phase 1b Clinical Trial of Topical Drop Formulation of AKB-9778 for Primary Open-Angle Glaucoma (POAG) in the Second Quarter of 2019

Bristol-Myers Squibb Company announced the Phase 3 CheckMate -498 trial evaluating Opdivo plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase-unmethylated glioblastoma multiforme did not meet its primary endpoint of overall survival at final analysis.

Spectrum Pharmaceuticals, Inc. announced the closure of an asset purchase and license agreement with ImmunGene, Inc., a privately held biotechnology company.

Alpine Immune Sciences, Inc. provided a corporate update and reported financial results for the first quarter ended March 31, 2019.

Allergan plc announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, Nevada.

Six-month follow-up on patients with cerebral adrenoleukodystrophy (cALD) shows stable neurological function scores and early and persistent resolution of brain inflammation on MRI

Customer satisfaction among commercial health plan members has improved nationwide, but health insurers are still confronting challenges when it comes to delivering on the financial and personal health expectations of their members.

Faberlic, one of the world’s leading manufacturer of patented oxygen skin care products (Aquaftem®, Novaftem® Oxygen Complex), has been recognized among the world’s 100 largest direct selling companies.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that 14 abstracts sponsored by Jazz Pharmaceuticals and one abstract from an investigator-sponsored trial will be presented at the 33rd Annual Meeting of the Associated Professional Sleep Societies, known as “SLEEP,” in San Antonio from June 8-12, 2019.